Overview Financials News + Filings Key Docs Charts Ownership Insiders
All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Inv. presentation
Quarterly results
CC transcript
|
|
Asterias Biotherapeutics, Inc. (AST)
|
Create: Alert |
All | News | Filings
| Date Filed | Type | Description |
| 03/20/2019 |
15-12B
| Form 15-12B - Securities registration termination [Section 12(b)]: |
| 03/20/2019 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/20/2019 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/20/2019 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
| 03/14/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/14/2019 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/14/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/14/2019 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/14/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/14/2019 |
POS AM
| Form POS AM - Post-Effective amendments for registration statement: |
| 03/14/2019 |
S-8 POS
| Form S-8 POS - Securities to be offered to employees in employee benefit plans, post-effective amendments: |
| 03/12/2019 |
4
| BROADWOOD PARTNERS, L.P. (See Remarks Below) has filed a Form 4 on Asterias Biotherapeutics, Inc.|
Txns:
| Disposed of 5,292,156 shares
@ $0 |
|
| 03/12/2019 |
SC 13D/A
| BROADWOOD PARTNERS, L.P. reports a 0% stake in Asterias Biotherapeutics, Inc. |
| 03/08/2019 |
8-K
| Completion of Acquisition or Disposition of Assets, Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Sta... |
| 03/08/2019 |
25-NSE
| Form 25-NSE - Notification filed by national security exchange to report the removal from listing and registration of matured, redeemed or retired securities: |
| 03/05/2019 |
4
| Wirth Edward (Chief Medical Officer) has filed a Form 4 on Asterias Biotherapeutics, Inc.|
Txns:
| Granted 156,452 shares
@ $0
Paid exercise price by delivering 48,826 shares
@ $0.95, valued at
$46.4k
|
|
| 03/05/2019 |
4
| Mulroy Michael H. (President and CEO) has filed a Form 4 on Asterias Biotherapeutics, Inc.|
Txns:
| Granted 252,606 shares
@ $0
Paid exercise price by delivering 76,588 shares
@ $0.95, valued at
$72.8k
|
|
| 03/05/2019 |
4
| Chavez Ryan Daniel (CFO and General Counsel) has filed a Form 4 on Asterias Biotherapeutics, Inc.|
Txns:
| Granted 145,263 shares
@ $0
Paid exercise price by delivering 44,471 shares
@ $0.95, valued at
$42.2k
|
|
| 03/01/2019 |
8-K
| Quarterly results |
| 03/01/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 02/28/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 02/04/2019 |
DEFM14A
| Form DEFM14A - Definitive proxy statement relating to merger or acquisition: |
| 01/24/2019 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 01/24/2019 |
GN
| Asterias Provides Top Line 12 Month Data Update for its OPC1 Phase 1/2a Clinical Trial in Severe Spinal Cord Injury |
| 01/04/2019 |
4
| Chavez Ryan Daniel (CFO and General Counsel) has filed a Form 4 on Asterias Biotherapeutics, Inc.|
Txns:
| Paid exercise price by delivering 20,440 shares
@ $0.68, valued at
$13.9k
|
|
| 01/04/2019 |
4
| Wirth Edward (Chief Medical Officer) has filed a Form 4 on Asterias Biotherapeutics, Inc.|
Txns:
| Paid exercise price by delivering 20,440 shares
@ $0.68, valued at
$13.9k
|
|
| 01/04/2019 |
GN
| BioTime Announces Management Changes Concurrent With Participation at 2019 J.P. Morgan Healthcare Conference and 2019 Biotech Showcase |
| 12/06/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 12/06/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 12/04/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 11/27/2018 |
GN
| Asterias Biotherapeutics Announces Fourth Patient Dosed in First-in-Human Clinical Study of Immunotherapy VAC2 in Non-Small Cell Lung Cancer |
| 11/09/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
| 11/09/2018 |
10-Q
| Quarterly Report for the period ended September 30, 2018 |
| 11/08/2018 |
425
| Form 425 - Prospectuses and communications, business combinations: |
|
|
|